New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
HIGHER: Cisco (CSCO), up 8% after reporting better than expected third quarter results. Avago (AVGO) is also up 0.6% and Cavium (CAVM) is up 3% following Cisco's report... Gentiva Health (GTIV), up 60% after Kindred Healthcare (KND) proposes to acquire the company for $14.00 per share in cash and stock... Advance Auto Parts (AAP), up 3.3% after raising its outlook... Clovis (CLVS), up 7.7% after reporting drug data at ASCO conference... Plug Power (PLUG), up 2.4% following upgrade at Cowen. DOWN AFTER EARNINGS: Wal-Mart (WMT), down 2.9%... Kohl's (KSS), down 3.6%... ExOne (XONE), down 15%... Real Goods Solar (RGSE), down 13.7%. ALSO LOWER: Bristol-Myers (BMY), down 4% following downgrade at BMO Capital citing last nights' ASCO abstracts discussing disappointing Nivo-Yervfoy combination data... VOXX International (VOXX), down 25% after downgraded at B. Riley following worse than expected Q4 results... Sorrento Therapeutics (SRNE), down 21% after 4.765M share secondary stock offering priced at $5.25... Incyte (INCY), down 9.7% after an abstract regarding a Phase 2 study of its pancreatic cancer drug was posted at ASCO... Liquid Holdings (LIQD), down 43.5% after its 32M share secondary priced at $1.25.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
November 16, 2015
12:21 EDTCLVSImmunoGen selloff on Clovis news unwarranted, says RBC Capital
Subscribe for More Information
11:42 EDTWMTWal-Mart volatility increases into Q3 and outlook
Subscribe for More Information
11:35 EDTKSSDillard's sinks to 52-week low after joining chorus of 'disappointed' retailers
Shares of Dillard's (DDS), a retailer of fashion apparel, cosmetics and home furnishing, are falling to their worst level in a year after the company became the latest in its industry to report lower than expected third quarter results. WHAT'S NEW: This morning, Dillard's reported Q3 earnings per share of $1.19 and revenue of $1.435B, narrowly missing analysts' consensus estimates of $1.20 and $1.49B, respectively. Same-store sales for the quarter fell 4%. Total merchandise sales decreased 3% for the 13-week period ended October 31. Weaker performing categories were men's apparel and accessories and ladies' accessories and lingerie with notable weakness in home and furniture the company explained. Dillard's Chief Executive Officer, William T. Dillard, II, stated, "We are disappointed with our third quarter sales performance and in the resulting decline in profit. Share buyback remained a high priority, and we repurchased $175 million of stock under our share repurchase program." WHAT'S NOTABLE: Gross margin from retail operations improved 11 basis points of sales for the 13 weeks ended October 31 compared to the prior year third quarter. Consolidated gross margin for the 13 weeks ended October 31 declined 30 basis points of sales compared to the prior year third quarter. The disparity between retail and consolidated gross margin performance is attributable to increased revenue at CDI, which is a substantially lower margin business. Inventory increased 6% at October 31 compared to November 1, 2014. For FY15, the company expects capital expenditures of $150M. PRICE ACTION: In late morning trading, Dillard's fell $5.81, or 7.5%, to $71.79 on more than three times its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week low of $68.05. Including today's pull back, the shares have lost about 36% over the past 12 months. OTHERS TO WATCH: Other apparel, cosmetics and home furnishing retailers include Macy's (M), Kohl's (KSS), JC Penny (JCP), Sears (SHLD) and Nordstrom (JWN).
11:15 EDTWMTEarnings Watch: Analysts largely downbeat on Wal-Mart after annual meeting
Wal-Mart Stores (WMT) is scheduled to report third quarter earnings before the market open on Tuesday, November 17, with a conference call scheduled for 7:00 am ET. Wal-Mart, a member of the Dow Jones Industrial Average, operates retail stores in various formats under 69 different banners in 27 countries with its "everyday low price" philosophy. EXPECTATIONS: Analysts are looking for earnings per share of 98c on revenue of $117.79B, according to First Call. The consensus range for EPS is $1.07-$1.15 on revenue of $114.86B-$119.57B. In its last earnings report, Wal-Mart forecast Q3 EPS of 93c-$1.05 with Q3 U.S. same store sales projected to grow 2%-3%. LAST QUARTER: Wal-Mart reported second quarter EPS of $1.08, missing analysts' estimate of $1.12, on revenue of $120.2B, beating analysts' estimate of $119.72B. The company said currency negatively impacted Q2 EPS by approximately 4c. Comp sales at Walmart U.S. increased 1.5%, driven by traffic of 1.3%, and Neighborhood Market comps increased approximately 7.3%. Global e-commerce sales for Q2 increased about 16%, the company said. Looking ahead, Wal-Mart cut its outlook for fiscal year 2016 EPS to $4.40-$4.70 from $4.70-$5.05 against estimates at that time for $4.77. Chief Financial officer Charles Holley said operating profit would be pressured for the remainder of the year, due to in store associate wages and additional hours, as well as headwinds from pharmacy reimbursements and ongoing shrink. The company said that the impact from investments in wages, training and additional hours in its stores and clubs will be approximately 24c, including approximately 8c in Q3. Additionally, the company said that along with pharmacy headwinds, higher than expected ongoing shrink in Walmart U.S. will impact full year EPS by around 11c, including about 3c in Q3. Further, the FY16 currency exchange rate impact is expected to be approximately 15c, up 2c from last quarter's revised guidance of 13c. NEWS: At its annual meeting on October 14, Wal-Mart forecast net sales growth of approximately 3% for FY16 excluding the impact of currency exchange fluctuations. The company forecast net sales growth of 3%-4% annually over the next three years, which will add about $45B-$60B in sales. Looking to fiscal year 2017, Wal-Mart forecast EPS down 6%-12% vs. FY16. Wal-Mart also said that the strong dollar is expected to reduce the company's FY15 revenue by $15B, Reuters said. Wal-Mart's board authorized a new $20B share repurchase program and said it expects operating income to bottom out in FY17. During the quarter, Reuters reported that Wal-Mart filed an application with the Federal Aviation Administration to test drones for home delivery, curbside pickup and warehouse inventory checks. The Wall Street Journal said Wal-Mart is slimming down its number of items in an attempt to bolster sales figures, yet the reduction has created tensions with suppliers. STREET RESEARCH: Credit Suisse, Stephens and BofA Merrill Lynch all downgraded Wal-Mart after the retailer's annual meeting based on guidance for declining earnings in FY17 and a lack of earnings growth until FY19. Baird, UBS and Jefferies all cut their price targets on Wal-Mart following the annual meeting. JPMorgan analyst Christopher Horvers said the "depth and degree" of the financial pressures addressed at the annual meeting were "much greater than anticipated." Ahead of the Q3 earnings report, Baird reiterated its Outperform rating and $70 price target and said Wal-Mart shares appear to hold some value for patient investors. Wal-Mart was upgraded to Buy from Neutral at Northcoast on November 13. PRICE ACTION: Wal-Mart shares are down over 21% over the last three months, but are up about 1% to $57.07 in late morning trading ahead of Tuesday's earnings report.
10:27 EDTCLVSGoldman puts Conviction Buy-rated Clovis under review
Subscribe for More Information
10:25 EDTAVGOUBS trims Apple target, says iPhone partner cut production forecast
Hon Hai, which manufactures Apple's (AAPL) iPhones, expects to assemble significantly fewer iPhones this quarter than in the same period in 2014, UBS wrote in a note to investors today. WHAT'S NEW: Hon Hai Precision Industry, also known as Foxconn, is expected to assemble 10% fewer iPhones this quarter than in the same period in 2014, said UBS analyst Steven Milunovich, citing work from fellow UBS analyst Arthur Hsieh. Previously, companies that supply force touch components for iPhones saw a 10%-15% reduction in their orders, the analyst reported. These developments "are not encouraging," but Apple had previously ordered a large number of iPhones for Q4, according to Milunovich. Overall iPhone demand "could still be decent," he believes. However, the analyst lowered his iPhone sales estimate for Apple's March quarter to 61M from 62.5M, asserting that iPhone sales on China's November 11 Singles Day holiday may have come in below expectations. Based on October search volumes, he continues to believe that demand for iPhone units in the fourth quarter of the calendar year will be 75M, in-line with the consensus outlook. Milunovich trimmed his price target on Apple to $140 from $150 but kept a Buy rating on the shares. WHAT'S NOTABLE In a note to investors on November 10, Credit Suisse reported that it was cutting its estimates for 2016 iPhone sales. The firm expects sales of the device to fall 10.4% in the first quarter versus the same period in 2015, and it predicts that iPhone sales will decline 5.5% year-over-year in 2016. Suppliers with greater than 10% exposure to Apple include Avago (AVGO), SanDisk (SNDK), Analog Devices (ADI), Broadcom (BRCM), Texas Instruments (TXN), NXP Semiconductors (NXPI) and Fairchild (FCS), Credit Suisse reported. The firm said it continues to have a negative view of the smartphone sector. PRICE ACTION: In early trading, Apple added nearly 1% to $113.34.
10:25 EDTKSSOptions with decreasing implied volatility
Subscribe for More Information
10:23 EDTCLVSClovis price target cut to $28 from $92 at Piper Jaffray
Piper Jaffray analyst Charles Duncan cut his price target for shares of Clovis Oncology (CLVS) to $28 from $92 after the company announced that rociletinib efficacy data matured and the number of patients with a confirmed response is lower than expected. The updated response rate may still ultimately be approvable, but it further hinders rociletinib's competitive positioning compared to AstraZeneca's (AZN) Targrisso, Duncan tells investors in a research note. The analyst pushed back his first rociletinib sales estimate to Q4 of 2016 and lowered the drug's peak penetration of the second line market from 25% to 45%. He reiterates a Neutral rating on Clovis. The stock is down 67%, or $66.93, to $32.50 in morning trading.
10:11 EDTCLVSHigh option volume stocks
Subscribe for More Information
09:19 EDTCLVSOn The Fly: Pre-market Movers
HIGHER: Nexvet Biopharma (NVET), up 16.8% after NV-01 study meets primary endpoint... Protalix BioTherapeutics (PLX), up 4.8% after announcing that it will conduct a Phase III clinical trial for PRX-102... Array Biopharma (ARRY), up 4.3% after announcing a commercialization collaboration with Pierre Fabre... Perrigo (PRGO), up 2.1% after being upgraded to Buy from Neutral at UBS. DOWN AFTER EARNINGS: Dillard's (DDS), down 11.7% after reporting quarterly results. ALSO LOWER: Clovis Oncology (CLVS), down 71.3% after the FDA requested additional clinical data for rociletinib... KaloBios Pharmaceuticals (KBIO), down 48.9% after announcing that it will wind down its operations... Starwood Hotels (HOT), down 6.3% after announcing that Marriott (MAR) will acquire the company... Marriott is down 2.4%... Five Below (FIVE), down 3.1% after being downgraded to Hold from Buy at Deutsche Bank.
09:10 EDTCLVSClovis volatility elevated into FDA requests added data for rociletinib
Subscribe for More Information
08:36 EDTWMTWal-Mart holds value for patient long-term investors, says Baird
Subscribe for More Information
08:32 EDTCLVSClovis reopens, down 64% after FDA requests added data for rociletinib
AstraZeneca (AZN), which is at work on a drug similar to rociletinib, is up 2.5% in pre-market trading.
08:13 EDTCLVSClovis to resume trading at 8:30 am ET
Subscribe for More Information
08:01 EDTCLVSClovis says FDA requests additional data for rociletinib
Subscribe for More Information
07:57 EDTCLVSClovis shares halted, news pending
Subscribe for More Information
07:40 EDTWMTBuffett says lower stakes in Goldman, Wal-Mart doesn't reflect lower confidence
Subscribe for More Information
07:36 EDTWMTBerkshire Hathaway discloses new AT&T stake in quarterly update
Berkshire Hathaway gave a quarterly update on its stakes in a filing this morning. NEW STAKES: AT&T (T), Kraft Heinz (KHC), Liberty Lilac Group (LILA). INCREASED STAKES: Phillips 66 (PSX), Charter (CHTR), Liberty Media (LMCK), Suncor (SU), General Motors (GM). DECREASED STAKES: Goldman Sachs (GS), Wal-Mart (WMT), Deere (DE), Chicago Bridge & Iron (CBI), WABCO (WBC). LIQUIDATED STAKES: Viacom (VIAB).
07:00 EDTBMYBristol-Myers announces data from Phase 3 ALLY-3+ trial for Daklinza
Bristol-Myers announced late-breaking data from the Phase 3 ALLY-3+ trial investigating a regimen of Daklinza in combination with sofosbuvir and ribavirin in genotype 3 hepatitis C patients with advanced fibrosis or cirrhosis, for treatment durations of 12 and 16 weeks. This patient population is one of the most difficult to treat, among whom sustained virologic response rates, or cure, have proved harder to achieve. The results show that 100% of patients in the advanced fibrosis cohort achieved SVR12 in both the 12- and 16-week arms of the study. SVR12 rates were 83% and 89% in patients with cirrhosis in the 12- and 16-week arms, respectively.
05:26 EDTCSCOEricsson CEO says no talks with Cisco about merger or acquisition
Ericsson (ERIC) has noted the recent speculation in the press and financial markets regarding an interest by Cisco (CSCO) to acquire Ericsson. On November 9, the two companies announced a global business and technology partnership to create the networks of the future. The partnership announcement was supported by multiple agreements that include commitments to network transformation through reference architectures and joint development, systems-based management and control, a broad reseller agreement, and collaboration in key emerging market segments. President, CEO and member of the board, Hans Vestberg says: "We note that there are rumors in the market regarding an acquisition of Ericsson by Cisco possibly spurred by the recent announcement of a partnership between our two companies. The talks leading up to the partnership announcement have been ongoing for a year and there have not been any discussions whatsoever on a merger or an acquisition."
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use